Telomir Enterprise Value Over E B I T D A from 2010 to 2024
| TELO Stock | 3.98 0.30 7.01% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter (18.14) | Current Value (19.05) | Quarterly Volatility 584.97521416 |
Check Telomir Pharmaceuticals, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Telomir Pharmaceuticals,'s main balance sheet or income statement drivers, such as Selling General Administrative of 724.7 K, Total Revenue of 0.0 or Other Operating Expenses of 4.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 63.3. Telomir financial statements analysis is a perfect complement when working with Telomir Pharmaceuticals, Valuation or Volatility modules.
Telomir | Enterprise Value Over E B I T D A |
Latest Telomir Pharmaceuticals,'s Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Telomir Pharmaceuticals, Common over the last few years. It is Telomir Pharmaceuticals,'s Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Telomir Pharmaceuticals,'s overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Telomir Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | (1,220) | |
| Coefficient Of Variation | (47.96) | |
| Mean Deviation | 450.52 | |
| Median | (1,501) | |
| Standard Deviation | 584.98 | |
| Sample Variance | 342,196 | |
| Range | 1.5K | |
| R-Value | 0.70 | |
| Mean Square Error | 188,952 | |
| R-Squared | 0.49 | |
| Significance | 0 | |
| Slope | 91.31 | |
| Total Sum of Squares | 4.8M |
Telomir Enterprise Value Over E B I T D A History
About Telomir Pharmaceuticals, Financial Statements
Telomir Pharmaceuticals, investors utilize fundamental indicators, such as Enterprise Value Over E B I T D A, to predict how Telomir Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | (18.14) | (19.05) |
Pair Trading with Telomir Pharmaceuticals,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Telomir Pharmaceuticals, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Telomir Pharmaceuticals, will appreciate offsetting losses from the drop in the long position's value.Moving together with Telomir Stock
| 0.88 | HLN | Haleon plc | PairCorr |
| 0.65 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.66 | ANRO | Alto Neuroscience, | PairCorr |
Moving against Telomir Stock
| 0.68 | FNMFO | Federal National Mortgage | PairCorr |
| 0.64 | KB | KB Financial Group | PairCorr |
| 0.62 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.54 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.49 | CIB | Bancolombia SA ADR | PairCorr |
The ability to find closely correlated positions to Telomir Pharmaceuticals, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Telomir Pharmaceuticals, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Telomir Pharmaceuticals, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Telomir Pharmaceuticals, Common to buy it.
The correlation of Telomir Pharmaceuticals, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Telomir Pharmaceuticals, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Telomir Pharmaceuticals, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Telomir Pharmaceuticals, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Telomir Pharmaceuticals, Correlation against competitors. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.63) | Return On Assets (0.84) | Return On Equity (6.87) |
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.